Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: A motion sickness medication

Journal of Microencapsulation

Volumn 24, Issue 2, 2007, Pages 109-116

  McDonough, J A ^a   Persyn, J T ^a   Nino, J A ^a   Dixon, H ^a   Boland, E J ^b   Wang, Z ^c   Putcha, L ^d  

^a SOUTHWEST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c WYLE LABORATORIES   (United States)

^d NASA HEADQUARTERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHYL CELLULOSE; PALM OIL; PHOSPHATE BUFFERED SALINE; PROMETHAZINE; SORBITAN LAURATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONCENTRATION RESPONSE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GEL; HISTOPATHOLOGY; MICROENCAPSULATION; MOTION SICKNESS; NEBULIZATION; NONHUMAN; NOSE IRRITATION; NOSE MUCOSA; PH; RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; CAPSULES; CELL LINE; CELL SURVIVAL; DRUG CARRIERS; GELS; HUMANS; LUNG; MOTION SICKNESS; NASAL MUCOSA; PROMETHAZINE; RATS;

EID: 33947644144     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.1080/09687860600945628     Document Type: Article

References (9)

1. Cowings, PS, Toscano, WB, DeRoshia, C. and Miller, NE (2000) Promethazine as a motion sickness treatment. Aviation & Space Environmental Medicine, 71, pp. 1013-1022.
2. Davis, JR, Vanderploeg, HM, Santy, PA, Jennings, RT and Stewart, DF (1988) Space motion sickness during 24 flights of the space shuttle. Aviation & Space Environmental Medicine, 59, pp. 1185-1189.
3. Illum, L. (2003) Nasal drug delivery-possibilities, problems, and solutions. Journal of Controlled Release, 87, pp. 187-198.
4. Lackner, JR and Graybiel, A. (1994) Use of promethazine to hasten adaptation to provocative motion. Journal of Clinical Pharmacology, 34, pp. 644-648.
5. Marttin, E., Verhoef, JC and Spies, F. (1999) The effect of methylated beta-cyclodextrins on the tight junctions of the rat nasal respiratory epithelium: Electron microscopic and confocal laser scanning microscopic visualization studies. Journal of Controlled Release, 57, pp. 205-213.
6. McDonough, JA (2004) Microcapsule formulation: Controlled release microcapsule formulation design for nasal delivery. Drug Delivery Technology, 4, pp. 44-47.
7. Persyn, JT, McDonough, JA, Nino, JA, Dixon, H. and Boland, EJ (2005) Mucosal delivery of cytotoxic therapeutic agents: Response of rat nasal mucosa to microencapsulated ethopropazine HCl enantiomer. Journal of Microencapsulation, 22, pp. 737-744.
8. Ramanathan, R., Geary, RS, Bourne, DWA and Putcha, L. (1998) Bioavailability of intranasal promethazine dosage forms in dogs. Pharmacology Research, 38, pp. 35-39.
9. Takeda, N., Morita, M. and Hasegawa, S. (1993) Neuropharmacology of motion sickness and emesis. Acta Otolaryngologica (Stockholm), 501, pp. 10-15.